1. Control of CD8 T cell proliferation and terminal differentiation by active STAT5 and CDKN2A/CDKN2B
- Author
-
Jacques A. Nunès, Magali Grange, Romain Roncagalli, Guylène Firaguay, Nathalie Auphan-Anezin, Anne-Marie Schmitt-Verhulst, Jacques Ghysdael, Amandine Mas, Marilyn Giordano, Centre d'Immunologie de Marseille - Luminy (CIML), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Institut Charles Gerhardt Montpellier - Institut de Chimie Moléculaire et des Matériaux de Montpellier (ICGM ICMMM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Université Montpellier 2 - Sciences et Techniques (UM2)-Institut de Chimie du CNRS (INC), Service d'hématologie-immunologie-oncologie pédiatrique [CHU Trousseau], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Charles Gerhardt Montpellier - Institut de Chimie Moléculaire et des Matériaux de Montpellier (ICGM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Nunès, Jacques
- Subjects
Adoptive cell transfer ,senescence ,CD8-Positive T-Lymphocytes ,MESH: Mice, Knockout ,Mice ,Interleukin 21 ,0302 clinical medicine ,STAT5 Transcription Factor ,Immunology and Allergy ,Cytotoxic T cell ,MESH: Animals ,IL-2 receptor ,Receptors, Immunologic ,Cellular Senescence ,transcription factor ,Mice, Knockout ,0303 health sciences ,ZAP70 ,Cell Differentiation ,MESH: Receptors, Antigen, T-Cell ,MESH: Cyclin-Dependent Kinase Inhibitor p15 ,Natural killer T cell ,MESH: CD8-Positive T-Lymphocytes ,MESH: Gene Expression Regulation ,Cell biology ,MESH: Cell Aging ,MESH: Cyclin-Dependent Kinase Inhibitor p16 ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,immunotherapy ,MESH: Cell Differentiation ,[SDV.IMM] Life Sciences [q-bio]/Immunology ,Immunology ,Receptors, Antigen, T-Cell ,Biology ,03 medical and health sciences ,MESH: Cell Proliferation ,Animals ,Lectins, C-Type ,Antigen-presenting cell ,MESH: Receptors, Immunologic ,MESH: Mice ,Cyclin-Dependent Kinase Inhibitor p16 ,Cell Proliferation ,Cyclin-Dependent Kinase Inhibitor p15 ,030304 developmental biology ,Interleukin 3 ,MESH: STAT5 Transcription Factor ,Original Articles ,Gene Expression Regulation ,Cancer research ,effector CD8 T cell ,gene regulation ,030215 immunology - Abstract
International audience; CD8 T cells used in adoptive immunotherapy may be manipulated to optimize their effector functions, tissue-migratory properties and long-term replicative potential. We reported that antigen-stimulated CD8 T cells transduced to express an active form of the transcription factor signal transducer and activator of transcription 5 (STAT5CA) maintained these properties upon adoptive transfer. We now report on the requirements of STAT5CA-expressing CD8 T cells for cell survival and proliferation in vivo. We show that STAT5CA expression allows for greater expansion of T cells in vivo, while preserving dependency on T-cell-receptor-mediated tonic stimulation for their in vivo maintenance and return to a quiescent stage. STAT5CA expression promotes the formation of a large pool of effector memory T cells that respond upon re-exposure to antigen and present an increased sensitivity to γc receptor cytokine engagement for STAT5 phosphorylation. In addition, STAT5CA expression prolongs the survival of what would otherwise be short-lived terminally differentiated KLRG1-positive effector cells with up-regulated expression of the senescence-associated p16(INK) (4A) transcripts. However, development of a KLRG1-positive CD8 T cell population was independent of either p16(INK) (4A) or p19(ARF) expression (as shown using T cells from CDKN2A(-/-) mice) but was associated with expression of transcripts encoding p15(INK) (4B) , another protein involved in senescence induction. We conclude that T-cell-receptor- and cytokine-dependent regulation of effector T cell homeostasis, as well as mechanisms leading to senescent features of a population of CD8 T cells are maintained in STAT5CA-expressing CD8 T cells, even for cells that are genetically deficient in expression of the tumour suppressors p16(INK) (4A) and p19(ARF) .
- Published
- 2015
- Full Text
- View/download PDF